The stock market is up Wednesday, with the Dow Jones Industrial Average up 0.61%, the Nasdaq up 0.54% and the S&P 500 up 0.46%. Today’s winners include a medical diagnostic developer who reported good results on a study and a medical device maker who reported higher than expected sales estimates for 2013. The sole loser is a for-profit educator continuing to struggle with declining enrollment.
These are Wednesday’s market winners and loser.
Biggest Winners
Shares of Rosetta Genomics Ltd. (NASDAQ: ROSG) are up 22.05% to $5.62 on trading volume of 2.8 million shares. The medical diagnostics developer’s shares rose following positive news of a tumor study. The 52-week high is $23.43.
Shares of NuVasive Inc. (NASDAQ: NUVA) are up 10.91% to $17.48 on trading volume of 1.5 million shares. The company, which makes devices to treat spinal problems, announced it would likely achieve sales of about $655 million in 2013, better than the $638.2 million analysts polled by Reuters had expected. The 52-week high is $25.99.
Biggest Loser
Shares of Apollo Group Inc. (NASDAQ: APOL) are down 8.98% to $19.06 on trading volume of 4.2 million shares. The for-profit educator, which is the parent company of the University of Phoenix, announced that enrollment in its programs declined by 14% and new students signing up for classes fell 15% for the quarter, the third straight quarter of declines. The 52-week high is $58.29.
Follow Samuel on Twitter: SWeigley
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
